Q2 2025 · 13F-HR
Redmile Group, LLCholdings as filed
Filed 2025-08-14 · accession 0001104659-25-078608
$939.6M
Reported value
48
Positions
2025-06-30
Period end
The Brief · Redmile Group, LLC · Q2 2025
AI · grounded in 13F
Redmile Group, LLC established a new position in SRRK valued at $139.2M. The fund also initiated new stakes in KRYS for $91.2M and ZYME for $52.1M. Other new additions include STOK at $49.7M and IMNM at $45.3M. The fund ended the period with 48 positions and total AUM of $939.6M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $139.2M | 14.8% | 3,929,039 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $91.2M | 9.71% | 663,471 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $52.1M | 5.54% | 4,150,627 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $49.7M | 5.29% | 4,375,931 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $45.3M | 4.82% | 4,872,225 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $43.3M | 4.61% | 4,664,791 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $42.5M | 4.53% | 3,732,888 | Common | SOLE |
| G5509L101 | LIVN | LIVANOVA PLC | $42.1M | 4.48% | 934,271 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $42.0M | 4.47% | 15,666,731 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $41.3M | 4.40% | 774,311 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $39.2M | 4.17% | 4,775,717 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $35.1M | 3.73% | 803,289 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $24.2M | 2.58% | 1,423,411 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $21.2M | 2.26% | 8,253,316 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $19.1M | 2.03% | 1,276,676 | Common | SOLE |
| 433313103 | HNGE | HINGE HEALTH INC | $15.5M | 1.65% | 300,000 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $15.2M | 1.61% | 1,545,208 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $15.1M | 1.61% | 6,300,644 | Common | SOLE |
| 31189P102 | FATE | FATE THERAPEUTICS INC | $14.4M | 1.53% | 12,872,946 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $12.6M | 1.34% | 2,164,777 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $10.4M | 1.11% | 1,448,040 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $10.3M | 1.10% | 729,515 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $9.3M | 0.99% | 1,915,926 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $9.2M | 0.98% | 85,301 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $9.1M | 0.97% | 432,494 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $8.3M | 0.88% | 740,261 | Common | SOLE |
| 15678C102 | CBLL | CERIBELL INC | $8.2M | 0.87% | 435,239 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $7.4M | 0.79% | 552,506 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $7.0M | 0.74% | 343,026 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $6.8M | 0.73% | 1,188,998 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $5.9M | 0.63% | 3,031,009 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $5.8M | 0.62% | 136,495 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $5.1M | 0.55% | 2,074,350 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $5.0M | 0.54% | 630,686 | Common | SOLE |
| 70975L107 | PEN | PENUMBRA INC | $4.8M | 0.51% | 18,818 | Common | SOLE |
| 82024L103 | STTK | SHATTUCK LABS INC | $4.4M | 0.47% | 5,539,724 | Common | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $3.4M | 0.36% | 441,701 | Common | SOLE |
| 449585108 | 1K0 | IGM BIOSCIENCES INC | $3.3M | 0.35% | 2,952,131 | Common | SOLE |
| N51517105 | 4PKB | LAVA THERAPEUTICS NV | $2.7M | 0.29% | 2,074,372 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $2.4M | 0.25% | 1,114,529 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $2.2M | 0.23% | 1,586,174 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $2.1M | 0.22% | 451,099 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $1.9M | 0.20% | 1,632,577 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $1.6M | 0.17% | 2,285,320 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $1.4M | 0.15% | 3,391,455 | Common | SOLE |
| 10170A100 | BOLD | BOUNDLESS BIO INC | $594,924 | 0.06% | 589,034 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $416,143 | 0.04% | 112,168 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $221,490 | 0.02% | 82,955 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.